Figure 3.

BMSC-derived exosome miR-181a treatment triggers the conversion of effector T cells into FOXP3⁺-expressing Tregs. (a) The frequency of CD4⁺CD25⁺FOXP3⁺ Treg cells in CD4⁺ T cells cocultured with BMSC-derived exosomes analyzed by flow cytometry. ^∗∗∗P < 0.001. (b) miR-181a expression in CD4⁺ T cells treated with NC or miR-181a inhibitor-transfected BMSC-derived exosomes measured by RT-qPCR assay. ^∗∗∗P < 0.001. (c) The frequency of CD4⁺CD25⁺FOXP3⁺ Treg cells in CD4⁺ T cells treated with NC or miR-181a inhibitor-transfected BMSC-derived exosomes analyzed by flow cytometry. ^∗∗∗P < 0.001. Data are the mean ± SD (n = 3 biological replicates).